Exelixis | La Marge Brute Sur Les Ventes



Gross Profit On Sales Changement Date
Acadia Pharmaceuticals USD 243.83M 19.91M 2025-06
Agios Pharmaceuticals USD 10.75M 3.11M 2025-06
Amgen USD 6.17B 624M 2025-06
AstraZeneca USD 11.98B 637M 2025-06
Bayer EUR 6.38B 1.74B 2025-06
BioMarin Pharmaceutical USD 670.47M 76.89M 2025-06
Bristol-Myers Squibb USD 8.9B 714M 2025-06
Cytokinetics 66.77M 165.03M 2025-06
Eisai JPY 160.05B 12.42B 2025-06
Eli Lilly USD 13.11B 2.61B 2025-06
Exelixis USD 548.79M 12.52M 2025-06
Genmab DKK 868M 195M 2025-06
Glaxosmithkline GBP 5.6B 94M 2024-12
Incyte USD 1.14B 151.67M 2025-06
Ionis Pharmaceuticals USD 448M 317.85M 2025-06
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 12.99B 224M 2025-06
Moderna USD 18M 1000K 2025-06
Neurocrine Biosciences USD 676.2M 112.8M 2025-06
Novartis USD 11.51B 1.12B 2025-06
Pfizer USD 10.88B 248M 2025-06
Sanofi EUR 5.36B 4.71B 2024-12
Takeda JPY 722.01B 50.69B 2025-06
Ultragenyx Pharmaceutical USD 143.49M 32.86M 2025-06
Xencor 43.61M 10.88M 2025-06


Exelixis La Marge Brute Sur Les Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.